A detailed history of Woodline Partners LP transactions in Ideaya Biosciences, Inc. stock. As of the latest transaction made, Woodline Partners LP holds 588,754 shares of IDYA stock, worth $16 Million. This represents 0.17% of its overall portfolio holdings.

Number of Shares
588,754
Previous 456,453 28.98%
Holding current value
$16 Million
Previous $16 Million 16.38%
% of portfolio
0.17%
Previous 0.16%

Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

BUY
$30.37 - $43.05 $4.02 Million - $5.7 Million
132,301 Added 28.98%
588,754 $18.7 Million
Q2 2024

Aug 14, 2024

BUY
$34.37 - $43.46 $1.05 Million - $1.32 Million
30,451 Added 7.15%
456,453 $16 Million
Q1 2024

May 15, 2024

BUY
$34.2 - $47.13 $408,450 - $562,873
11,943 Added 2.88%
426,002 $18.7 Million
Q4 2023

Feb 14, 2024

BUY
$24.59 - $35.83 $4.27 Million - $6.22 Million
173,631 Added 72.22%
414,059 $14.7 Million
Q3 2023

Nov 14, 2023

BUY
$21.07 - $29.77 $1.34 Million - $1.89 Million
63,404 Added 35.82%
240,428 $6.49 Million
Q2 2023

Aug 14, 2023

BUY
$13.33 - $25.53 $2.36 Million - $4.52 Million
177,024 New
177,024 $4.16 Million
Q1 2022

May 16, 2022

SELL
$11.18 - $24.02 $5.57 Million - $12 Million
-498,187 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$20.95 - $26.88 $7.41 Million - $9.51 Million
353,808 Added 245.06%
498,187 $11.8 Million
Q3 2021

Nov 15, 2021

SELL
$17.26 - $27.08 $1.59 Million - $2.5 Million
-92,316 Reduced 39.0%
144,379 $3.68 Million
Q2 2021

Aug 16, 2021

SELL
$17.76 - $24.83 $945,791 - $1.32 Million
-53,254 Reduced 18.37%
236,695 $4.97 Million
Q1 2021

May 17, 2021

BUY
$13.48 - $23.77 $3.91 Million - $6.89 Million
289,949 New
289,949 $6.81 Million

Others Institutions Holding IDYA

About IDEAYA Biosciences, Inc.


  • Ticker IDYA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 48,067,700
  • Market Cap $1.31B
  • Description
  • IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinica...
More about IDYA
Track This Portfolio

Track Woodline Partners LP Portfolio

Follow Woodline Partners LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Woodline Partners LP, based on Form 13F filings with the SEC.

News

Stay updated on Woodline Partners LP with notifications on news.